Pectolinarigenin alleviates psoriasis via inhibition of keratinocyte hyperproliferation and inflammatory signaling
- 22 July 2026
- journal article
- Published by Elsevier in International Immunopharmacology
- Vol. 187, 117164
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Zhejiang Province
This publication has 28 references indexed in Scilit:
- Histone Modifications and DNA Methylation in Psoriasis: A Cellular PerspectiveClinical Reviews in Allergy & Immunology, 2025
- The Immunology of Psoriasis—Current Concepts in PathogenesisClinical Reviews in Allergy & Immunology, 2024
- Keratinocyte FABP5-VCP complex mediates recruitment of neutrophils in psoriasisCell Reports, 2023
- The emerging role of fatty acid binding protein 5 (FABP5) in cancersDrug Discovery Today, 2023
- Pectolinarigenin shows lipid‐lowering effects by inhibiting fatty acid biosynthesis in vitro and in vivoPhytotherapy Research, 2022
- Pectolinarigenin acts as a potential anti-osteosarcoma agent via mediating SHP-1/JAK2/STAT3 signalingBiomedicine & Pharmacotherapy, 2022
- Neuroprotective and anti-inflammatory effect of pectolinarigenin, a flavonoid from Amazonian Aegiphila integrifolia (Jacq.), against lipopolysaccharide-induced inflammation in astrocytes via NFκB and MAPK pathwaysFood and Chemical Toxicology, 2021
- FABP5 as a novel molecular target in prostate cancerDrug Discovery Today, 2020
- Bcl‐3 induced by IL‐22 via STAT3 activation acts as a potentiator of psoriasis‐related gene expression in epidermal keratinocytesEuropean Journal of Immunology, 2017
- In vitro biological evaluation of novel 7-O-dialkylaminoalkyl cytotoxic pectolinarigenin derivatives against a panel of human cancer cell linesBioorganic & Medicinal Chemistry Letters, 2008